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The identification of proteins differentially expressed between cancer and normal cells is vital
for the development of cancer diagnostics, therapeutics and vaccines. Using a ProteinChip
Biomarker System (Ciphergen Biosystems, Fremont, CA) which combines ProteinChip™
technology with time-of-flight mass spectrometry, we have developed a simple method to
screen and identify differentially secreted proteins from tumor cell lines. Mass spectra of the
range of proteins secreted from normal B-cells were generated along with those secreted from
Epstein-Barr virus transformed B-cells. A mass peak at m/z  4972.1 that was highly
over-represented in the transformed B-cell line was chosen for identification and purified by
reversed phase chromatography with concomitant monitoring of fractions by SELDI-TOF MS.
The resulting purified protein was digested with trypsin and the peptide masses derived from
the SELDI-TOF spectrum were used to search the public databases for protein identification.
Fragment matching of the resulting peptides identified the protein as thymosin -4. Using
LC-electrospray ionization MS/MS, the identity of this protein was confirmed. Thymosin -4
is a known marker in LCLs establishing the utility of this method to discover and identify
proteins differentially expressed between cancers and their matched normal
counterparts. (J Am Soc Mass Spectrom 2003, 14, 760–765) © 2003 American Society for Mass
Spectrometry
Modern cancer therapy and diagnosis relies onthe availability of targets unique to tumorcells. Development of novel therapeutics and
diagnostic agents is greatly facilitated by the discovery
of proteins that are differentially expressed between
cancerous and normal cells. These proteins can then be
used as targets for the development of small molecule
inhibitors, ELISA-based diagnostics, and functional
monoclonal antibodies that may block vital pathways,
deliver a toxic compound to the tumor, or cause apo-
ptosis by stimulating a tumor-specific surface molecule.
Such rationally designed therapies are far less likely to
have the broad toxicities associated with current che-
motherapy and may replace standard chemotherapy in
the future. Indeed, some of these targeted cancer treat-
ments are already on the market or in advanced clinical
trials and are showing great promise in efficacy and
reduced toxicity [1].
A major hurdle for developing new drugs of this
type is finding a target that is specific for the tumor.
Advances in the use of DNA biochips and real time
PCR have accelerated the discovery of new candidate
markers, but are not optimal for a number of reasons:
increased transcription of a gene does not necessarily
correlate with higher protein levels, differentially mod-
ified targets will be missed by this approach, and it is
difficult to select a sub-cellular localization to focus
discovery efforts on. Using combinations of mass spec-
trometry and 2-D gels different groups have been
successful in directly identifying differentially ex-
pressed proteins between various samples [2, 3].
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A simplification of this type of method may be the
use of Ciphergen’s ProteinChip™ Array technology
which utilizes the surface enhanced laser desorption/
ionization (SELDI) process to integrate protein capture,
purification, characterization and quantitative protein
interaction assays on a single biochip based platform
[4]. Briefly, ProteinChip™ Arrays contain multiple
spots derivatized with chemical or biological “docking
sites” which are used for the selective capture of pro-
teins and peptides from complex mixtures. After the
sample is applied to the surface, unbound proteins and
interfering substances (i.e., salts, detergents, urea) are
washed away, an energy-absorbing molecule (EAM), or
matrix, is added and the array is analyzed by laser
desorption ionization time-of-flight mass spectrometry.
Prior to spotting, a biochemical fractionation can be
used to select proteins of a specific type such as mem-
brane or secreted proteins. The use of this Protein-
Chip™ Biomarker System to profile differential protein
expression has been described for other cancers such as
prostate, breast, and ovarian cancer [5–8]. In this report
we combine high pressure liquid chromatography
(HPLC), SELDI, and electrospray ionization-tandem
MS to screen, isolate, and identify differentially secreted





chloride, ammonium acetate, phosphate buffered saline
(PBS), glycine, methanol, silver nitrate, and sodium
thiosulfate were obtained from Sigma (St. Louis, MO).
Acetonitrile was from Mallinckrodt Laboratory Chem-
icals (Phillipsburg, NJ). All other reagents were of the
highest quality commercially available.
Enrichment of CD19 Cells from PBMC
Peripheral blood mononuclear cells (PBMC) were en-
riched for CD19 cells by depletion of T lymphocytes,
monocytes, and NK cells. PBMC from two donors were
pooled and depleted of adherent cells by incubation for
2 h at 37 °C in tissue culture flasks. The non-adherent
population was collected in a 15 mL conical tube and
incubated with monoclonal antibodies (mAb) against
CD4, CD8, CD14, CD16, and CD56 (Pharmingen, San
Diego, CA) at 1 g mAb/106 cells in PBS for 1 h on ice.
The cells were then collected by centrifugation, washed
in PBS to remove unbound Ab, and resuspended in PBS
at 10  106 cells/mL. Goat anti-mouse magnetic IgG
Dynabeads (Dynal, Norway), washed according to the
manufacturer’s recommendation, were then added at
107 beads/mL of cells, and the mixture was incubated
for 30 min at room temperature while rotating. The
negatively selected cells were then removed from the
cell suspension by placing the tube in a Dynal Magnetic
Particle Concentrator (MPC), and the supernatant con-
taining the CD19 enriched cell population was col-
lected.
Immortalization of B lymphocytes by Epstein-Barr
Virus (EBV)
10 106 PBMC, from the same donors that were used to
enrich for CD19 cells, were pelleted and resuspended
in 9 mL of culture supernatant from the marmoset cell
line B95-8, which is EBV transformed and releases high
titers of transforming EBV. An additional 9 mL of
Roswell Park Memorial Institute (RPMI) medium
(Gibco Life Technologies, Gaithersburg, MD) contain-
ing 10% FBS (HyClone, Logan, UT), plus 1 g/mL
cyclosporin A (Sandoz, Basel, Switzerland) was added
to the culture. The cells were cultured in a T-25 tissue
culture flask, standing upright. After approximately
three weeks in culture, the B-lymphocytes will be
immortalized to an LCL, which was expanded conser-
vatively in RPMI/10% FBS.
SELDI Analysis of Secreted Proteins
Ten L of LCL and B-cell supernatants were spotted
onto a reversed phase H4 (hydrophobic surface) Pro-
teinChip™ Array in 5% acetonitrile, 0.05% trifluoroace-
tic acid, and incubated in a humid environment for 20
min at room temperature. A 10 L wash with 5%
acetonitrile, 0.05% trifluoroacetic acid was performed.
After drying, 0.5 L of a saturated solution of sinapinic
acid in 50% acetonitrile(vol/vol), 0.5% trifluoroacetic
acid (vol/vol) was applied to the spots and allowed to
dry prior to mass analysis in a ProteinChip™ Reader
(Ciphergen Biosystems). Calibration was performed in
parallel using protein standards spanning molecular
masses from 8564.8 Da (Ubiquitin) to 147,300 Da (Bo-
vine IgG).
SELDI Analysis of RP-HPLC Fractions
Peak fractions from reversed phase separation of LCL
and B cell supernatants were spotted directly on an H4
ProteinChip™ Array surface in order to monitor puri-
fication of the m/z  4972 species. 1 L of diluted
sample was put onto the array and allowed to dry.
Under other conditions in which buffers incompatible
with subsequent mass analysis (i.e., detergents, urea,
salts) are present, the ProteinChip™ Array is washed to
remove interfering substances. 0.5 L of saturated
-cyano-4-hydroxy cinnamic acid in 0.5 % trifluoroace-
tic acid, 50 % acetonitrile and 49.5% water was then
added to each spot and allowed to dry prior to mass
analysis as described above.
Protein Purification
One hundred L of secreted protein supernatant (see
above) was loaded onto a Supelco (Bellefonte, PA)
Discovery cyano reversed phase column (10 cm  3
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mm, 5 m ). Unbound compounds were washed out in
buffer A (water, 0.05% TFA) and proteins were eluted
with a linear gradient to 100% buffer B (acetonitrile,
0.05% TFA) over 17 column volumes. Peak fractions
were dried onto an H4 ProteinChip™ Array and ana-
lyzed by SELDI-MS as described above. Purified frac-
tions containing the mass of interest were pooled and
used for further study.
Trypsin Digestion and Analysis by SELDI
Twenty L of purified protein were heated for 1 min at
100 ° C. Protein was rapidly cooled on ice and conden-
sate spun down. The pH was brought to 7.5 with 1M
Tris pH  10.0 and sequencing grade modified porcine
trypsin (Promega, Madison, WI) was added to 0.05
g/mL. The protein was digested for 1 h and the
reaction stopped by spotting and drying onto an H4
ProteinChip™ Array. 0.5 L of alpha-cyano-4-hydroxy
cinnamic acid in 50% acetonitrile (vol/vol), 0.5% triflu-
oroacetic acid (vol/vol) was added and mass analysis
performed. External Calibration was performed using a
mixture of peptide standards in the same matrix on a
different spot of the array. Three molecular mass stan-
dards were used (parentheses indicate predicted molec-
ular masses): Dynorphin A (2147.5 Da), Glu1-Fibrino-
peptide B (1570.6 Da), and human ACTH (2933.5 Da).
Capillary LC-Electrospray Ionization-Tandem
Mass Spectrometry (LC-ESI-MS/MS)
A capillary column (100 m i.d., 12 cm long) was filled
with C18 resin. Peptides were bound to this column and
eluted by a gradient from 5 to 65% B over 20 min (A,
0.2% acetic acid in water; B, 80% acetronitrile in A).
Eluted peptides were introduced into the LC-Q ion-trap
mass spectrometer (Finnigan, CA) by electrospray via
an electrospray ionization interface (Cytopeia, Seattle,
WA) and analyzed by data dependent MS and MS/MS
scans. The collision induced dissociation spectra gener-
ated during the experiment were searched against a
human protein database using the SEQUEST program
of the Xcalibur software package version 1.2 [9] to
identify possible sequence matches. A second database
was created using possible variants of thymosin -4
following initial identification to account for removal of
the N-terminal methionine and acetylation.
Results and Discussion
After incubation of the cells with PBS, cell supernatants
were analyzed on a variety of ProteinChip™ Array
chemical surfaces to characterize protein expression
patterns. The use of on-spot chromatography, binding
the proteins to the reversed phase matrix on the Pro-
teinChip™ Array, and washing off salts and other
impurities allowed for the quick analysis of crude
secreted material. The SELDI mass spectrum revealed
different protein profiles of the two cell samples chosen
(Figure 1). The major differences between the two
samples are tabulated in Table 1. Due to the fact that the
isolated B cell population from patients did not com-
pletely consist of B-cells, proteins that are seen only in
the patient B-cell sample and not the LCL sample
cannot be attributed to down-regulation of these pro-
teins in LCL. Therefore, while it is possible that the
major peaks seen in the B-cell isolate (Table 1) are really
down regulated in LCL it is equally possible that these
Figure 1. SELDI mass spectrum for differentially expressed molecules. B-cells (a) and EBV-
transformed B-cells (b) were spun down, washed three times in PBS and incubated in PBS for 1 h at
room temperature. 2 L of each sample was spotted onto the array and treated as described in
Materials and Methods. The m/z range from 0 to 22,000 is shown here. Strong signal for a molecule at
m/z  4972 was present in EBV-transformed B-cells. This peak (labeled with an asterisk) was selected
for further analysis. The peak is seen at a slightly higher molecular mass than in the following
experiments due to the fact that standardization was performed here for a wide range of masses from
8 to 147 kDa, but is still an acceptable deviation from the expected mass (0.14%).
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are artifacts derived from isolating native cells. How-
ever, proteins that are seen in the LCL and not in the
B-cell population are LCL unique as this is a B-cell line
free of other cell types. Thus, we set out to validate our
method by choosing one of the LCL specific molecules
and looking to see if it has a known implication in
EBV-transformed B-cells.
The most prominent peak identified was the species
at m/z  4972.1 indicated in Figure 1. We wanted to use
multiple methods to determine the identity of this peak:
LC-ESI-MS/MS and SELDI analysis of tryptic frag-
ments followed by database searching of the tryptic
fingerprint. However, the unpurified LCL supernatant
was deemed too crude for further analysis and was
subjected to reversed phase HPLC to enrich and purify
the target peak. Fractions were monitored by SELDI-
TOF MS on material dried directly onto a Protein-
Chip™ Array after elution. The mass of interest was
identified in a peak eluting early off of the reversed
phase column (Figure 2). This sample was relatively
free of other detected masses and used for subsequent
analysis.
A more exact mass of the protein was determined by
standardizing the ProteinChip™ Reader using smaller
peptides rather than the large range of peptide and
protein standards used in the initial screen. This led to
the determination that there are two dominant peaks in
the purified fraction with m/z 4962.3 and m/z 4981.8
(Figure 3a). Subsequent analysis (below) revealed that
the protein is thymosin -4 and exists in a major
oxidized state. The predicted masses for the full protein
and its oxidized counterpart are 4964.5 and 4980.5
respectively, in good agreement with the determined
m/z values.
Following characterization of the parent protein we
wanted to use trypsin digestion to identify the protein
by its mass fingerprint (Figure 3b). The protein in the
HPLC fraction was digested with trypsin and subjected
to SELDI-TOF MS and m/z values tabulated. The deter-
mined m/z after digestion are indicated in Table 2, and
were used to search a database for matches using the
MS-FIT algorithm [10]. As the protein was not digested
under denaturing conditions and was trypsinized for a
relatively short time we allowed for a number of missed
cleavages in the MS-FIT menu. A match for thymosin 
was found in the results of the initial search. This was
Table 1. Major peaks with different intensities between LCL
and the B-cell population








aExamination of the spectra from Figure 1 reveals major differences
between LCL and the normal B-cell population. Peaks that are much
higher in the B-cell population could be derived from impurities in the
isolated native B-cells. Thus, the ones that showed higher levels in the
LCL were examined more closely. Of these, the peak at m/z of 4972.1
was the most striking difference.
Figure 2. Reversed Phase Chromatography of cell supernatant. 100L of LCL supernatant in PBS
were injected onto a SUPELCO Cyano reversed phase column and eluted with a water 0.5% TFA to
acetonitrile 0.5% TFA gradient. Fractions were collected and analyzed on an H4 ProteinChip™ Array
for signal at m/z  4972. The peak fraction containing highly purified peptide (indicated by an
asterisk) was used for all further analyses.
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Figure 3. (a) SELDI Mass Spectrum of Purified Protein. Purified protein from the reversed phase
chromatography was diluted 1:10 and spotted as described. Determined masses (m/z): ThyB: 4962.3,
ThyB-Ox: 4981.8 (resolution, t/2dt  532.7); predicted masses (Da): ThyB: 4964.5; ThyB-Ox: 4980.5. In
secreted forms of thymosin -4 it has been observed that there is a significant portion of oxidized
protein present. (b) SELDI Mass Spectrum of tryptic digest of the purified protein. 40 ng of trypsin
were added to 100 L of purified protein in ammonium bicarbonate and digested for 1 h at 37 °C. A
control of trypsin alone was run in parallel. Peaks unique to the ThyB digest are marked with capital
letters and are tabulated in Table 2.
Table 2. Predicted and determined m/z values for thymosin -4 tryptic digest
m/z Determineda m/z Predictedb Error (%) Amino acids in thymosin -4c Comments
A 1695.9 1695.9 0.00 1–14 (acetyl) N–terminus acetylated
B 1711.4 1711.0 0.023 1–14 (acetyl  Ox) Oxidized Met
C 1985.9 1986.2 0.015 26–43
* –– –– –– –– Trypsin autolysis
D 2230.8 2230.4 0.018 20–38
* –– –– –– –– Trypsin autolysis
E 2358.9 2358.6 0.013 19–38
* –– –– –– –– Trypsin autolysis
F 2600.5 2600.0 0.019 17–38
G 2703.2 2702.9 0.011 20–43
H 2831.6 2831.1 0.018 19–43
I 3072.7 3072.4 0.010 17–43
aTabulated are m/z values from the spectrum in Figure 3b.
bPredicted masses are those derived from a MS-Digest [10] run on the published sequence of thymosin -4 while accounting for the N-terminal
acetylation.
cPeptide fingerprinting searches with the non-tryptic fragments using the MS-FIT program [10] pull out human thymosin -4 as atop hit matching
all input fragments.
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the only protein which had an appropriate parent mass
and good matches for the generated peptides. After
allowing for N-terminal modifications [11] and methi-
onine oxidation [12] thymosin -4 was the top protein
pulled out by peptide fingerprinting.
To further verify the identity of the protein as
thymosin -4, LC-ESI-MS/MS was performed on the
purified and digested protein fraction. Numerous pep-
tides derived from thymosin -4 were identified and
gave coverage of almost 90% after allowing for N-
terminal acetylation (Table 3). The biochemical profile
of the material isolated from LCL secretions is one of a
protein without its initiating methionine that is modi-
fied by acetylation of the N-terminal serine. The me-
thionyl residue at position 6 is in a mixed state partially
oxidized to its sulfoxide equivalent. These findings are
in good agreement with the known properties of thy-
mosin -4: it is acetylated at the N-terminal serine and
exists in a mixed form between thymosin -4 and
thymosin -4 sulfoxide when secreted (see also Figure
3a).
Intracellular thymosin -4 is thought to be a G-actin
sequestering molecule [13], while when secreted [14],
especially as the thymosin -4 sulfoxide, the molecule
appears to act as a signaling molecule functioning in a
number of ways including wound healing [11], inflam-
mation [12], and hematopoesis [15]. Previous studies on
cell lines have shown that thymosin -4 is overex-
pressed on the mRNA and protein level in various cell
lines [16]. LCL had the highest amount of thymosin -4
in these studies. Although the function of thymosin -4
in cancer has not been completely elucidated, it is
known that numerous tumor types overexpress this
protein possibly for its involvement in apoptosis [17] or
angiogenesis [11]. The results of this study show that
the use of SELDI technology on relatively crude sam-
ples of tumor derived material can lead to the rapid
identification of tumor specific markers when a
matched normal control sample is present. The Protein-
Chip™ technology can be combined with other bio-
chemical and mass spectrometric methods to purify and
accurately characterize a target within a short period of
time. Further studies combining these techniques
should lead to the identification and characterization of
novel markers to be used as targets for rational design
of tumor-specific therapies.
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Table 3. Peptides determined by LC-ESI-MS/MS
Amino acids in thymosin -4a Matching sequence for MS/MS
Corresponding peptide
from SELDI Analysis
1-11 (acetyl) *SDKPDMAEIEK –





Known sequence 1-43 *SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES-b
aHighly significant hits from SEQUEST search of collision induced dissociation fragmentation of LC-ESI-MS tryptic digest of peak fraction. Shown
in bold is the published sequence of thymosin -4. Identified peptides: 1-14 (as acetyl derivative), 19-38, 19-43 (C-terminus), 20-38, 26-38, 20-43
(C-terminus), 1-11 (as acetyl derivative), 20-31. Total coverage: 88%
b*indicates N-terminal acetylation, -indicates the C-terminus.
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